focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

Annual Report and Accounts

11 Apr 2013 07:00

RNS Number : 0702C
Cathay International Holdings Ld
11 April 2013
 

Cathay International Holdings Limited

("Cathay" or the "Company")

 

Annual Report and Accounts

 

Hong Kong, 11 April 2013 - Cathay International Holdings Ltd. (LSE: CTI.L), an investment holding company and a leading investor in the growing healthcare sector in the People's Republic of China, today announces that its Annual Report and Accounts for the financial year ended 31 December 2012 together with the Notice of Annual General Meeting ("AGM"), Form of Direction and Form of Proxy for its forthcoming AGM have been posted to shareholders. These documents will also be uploaded to the National Storage Mechanism. An electronic copy of the Annual Report and Accounts is also now available on the Company's website at http://www.cathay-intl.com.hk and printed copies are available upon request.

 

- ENDS -

 

For further enquiries, please contact:

 

Cathay International Holdings Limited

Eric Siu (Finance Director)

Patrick Sung (Director and Controller)

 

Tel: +852 2828 9289

 

M:Communications

Mary-Jane Elliott / Amber Bielecka / Claire Dickinson

 

 

Tel: +44 (0)20 7920 2330

 

About Cathay

Cathay International Holdings Limited (CTI.L) is an investment holding company and a leading investor in the growing healthcare sector in the People's Republic of China ("PRC"). Taking advantage of the strong and growing domestic demand for high quality healthcare products in China, Cathay aims to identify investment opportunities with emphasis on high growth healthcare markets and build them into market sector leaders, with a clear exit strategy. Cathay has already demonstrated a strong track record of identifying high-growth potential investment opportunities in this area including: Lansen Group, China's leading specialty pharmaceutical company focused on rheumatology, Haotian Group, a company engaged in the manufacture, marketing and sale of key active ingredients for healthcare products, including dietary supplement inositol and Botai, a company engaged in the development of pharmaceutical products and bringing these to the growing Chinese market.

 

The Group employs more than 2,000 people across the PRC, including over 30 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen. Cathay also has a private equity investment arm focused on minority investment opportunities and a hotel investment.

 

For more information please visit the Company's website: www.cathay-intl.com.hk

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACSSFAFMSFDSEEL

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.